Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications

Accelerated approval for patients with microsatellite instability-high or mismatch repair deficient solid tumors is the first time the US FDA has granted an indication that does not specify the location of the tumor – a change precision medicine researchers have been eager to make.